Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C

Reviews in Gastroenterological Disorders

Volumn 3, Issue 2, 2003, Pages 93-109

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Chronic hepatitis C; Peginterferon alfa 2a; Peginterferon alfa 2b; Pegylated interferon; Ribavirin

Indexed keywords

AMANTADINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; BODY WEIGHT DISORDER; CELL PROLIFERATION; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG PACKAGING; DRUG RECEPTOR BINDING; DRUG STORAGE; DRY SKIN; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENETIC TRANSCRIPTION; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; IMMUNOMODULATION; INSOMNIA; IRRITABILITY; LIVER BIOPSY; MENTAL CONCENTRATION; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NEUTROPENIA; PHARYNGITIS; PROTEIN PROTEIN INTERACTION; PRURITUS; REVIEW; RIGOR; SKIN MANIFESTATION; VERTIGO; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

ADULT; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037840261     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Sievert W. Management issues in chronic viral hepatitis: hepatitis C. J Gastroenterol Hepatol. 2002;17:415-422.
2. National Institutes of Health. Consensus Development Conference Statement: Management of Hepatitis C: 2002. NIH Consensus Development Program; June 10-12, 2002; Bethesda, MD; 19(1). Available at: http://consensus.nih.gov/cons/116/116cdc_intro.htm. Accessed November 25, 2002.
3. Leung NW. Management of viral hepatitis C. J Gastroenterol Hepatol. 2002; 17(suppl):S146-S154.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
6. Pegasys® [package insert]. Nutley, NJ: Hoffman-La Roche Inc; October 2002.
7. PEG-Intron® [package insert]. Kenilworth, NJ: Schering-Plough Corporation; July 2002.
8. Copegus™ [package insert]. Nutley, NJ: Hoffman-La Roche Inc; December 2002.
9. Nucci ML, Short R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev. 1991;6(2):133-151.
10. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Sys. 1992;9(3-4):249-304.
11. Katre NV. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv Drug Deliv Rev. 1993;10(1):91-114.
12. Algranati NE, Sy S, Modi M. A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of pegINF a-2a (PEGASYS) and may explain its enhanced efficacy in chronic hepatitis C (CHC) [abstract]. Hepatology. 1999;30(4 pt 2):120.
13. Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72:217-224.
14. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther. 2002;24:1363-1383.
15. Platis D, Germain C, Lombardi G, Foster G. Immunomodulatory properties of pegylated interferons: the 40KD pegylated IFN alfa 2a has greater TH1 stimulatory activity than the 12KD pegylated IFN alfa 2b. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 136.
16. Rebetol® [package insert]. Kenilworth, NJ: Schering-Plough Corporation; September 2002.
17. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-567.
18. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32:647-653.
19. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
20. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
21. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40kd) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and the RBV dose. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 536.
22. Baker R. Pegasys plus ribavirin produces highest sustained virological response (SVR) rate ever achieved for patients with HCV genotype 1. Hepatitis C News Stories. [HIV and Hepatitis.com Web site]. April 18, 2002. Available at: www.hivandhepatitis.com/hepnews/041902a.html. Accessed December 12, 2002.
23. Cooksley WG, Lai M, Piratvisuth T, et al. HBeAg-positive chronic hepatitis B (CHB) patients with difficult-to-treat disease: improved response rates with peginterferon alfa-2a (40KD) (PEGASYS®) compared with conventional interferon alfa-2a. Abstract presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002; Boston, MA. Hepatology. 2002;36(4). Abstract 846.
24. Neumann AU, Zeuzem S, Ferrari C, et al. Ditto-HCV early viral kinetics report: novel decline patterns in gen 1 but not gen 2-3 patients treated with peg-interferon-alfa-2a and ribavirin. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 565.
25. Gane E, Chapman B, Holland J, et al. Viral kinetics of combination pegylated interferon a-2A and ribavirin in patients with hepatitis C cirrhosis. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 5301.
26. Brandao CE, Perez-Gomez R, Pessoa MG, et al. Prospective evaluation of early virologic response associated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin from a phase IV, randomized study examining the effects of treatment duration in hepatitis C patients infected with genotype 1. Abstract presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002; Boston, MA. Abstract 101915.
27. Bruno R, Debiaggi M, Ciappina V, et al. Hepatitis C virus (HCV) dynamics during therapy with peginterferon alfa-2a (40KD) (PEGASYS®) compared to peginterferon alfa-2b (12KD) (PEG-Intron® in naïve patients with chronic hepatitis C (CHC). Abstract presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002; Boston, MA. Abstract 102172. Hepatology. 2002;36(4 pt 2). Abstract 159.
28. Sulkowski MS, Reindollar R, Yu J. Pegylated interferon alfa-2a (Pegasys™) and ribavirin combination therapy for chronic hepatitis C: a phase II open-label study [abstract]. Gastroenterology. 2000;118(4 suppl 2):236.
29. Sulkowski MS, Reindollar R, Yu J. Combination therapy with peginterferon alfa-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): a phase II open-label study [abstract]. Hepatology. 1999;30(4 pt 2):197A. Abstract 145.
30. Goncales F, Bernstein DE, Berg C, et al. Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin in chronic hepatitis C: retreatment of patients who relapsed virologically after 24 weeks of therapy. Abstract presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002; Boston, MA. Abstract 102870. Hepatology. 2002;36(4 pt 2). Abstract 794.
31. Herrine SK, Brown R, Esposito S, et al. Efficacy and safety of peginterferon alfa-2a (PEGASYS®) combination therapies in patients with chronic hepatitis C (CHC) who relapsed on interferon alfa-2b plus ribavirin (REBETRON®) therapy. Abstract presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002; Boston, MA. Abstract 100934.
32. Di Bisceglie AM, Bernstein DE, Rustgi VR, et al. Pegylated (40KDA) interferon alfa-2a (Pegasys™) in new combination therapies: a preliminary report of a randomized, multicenter efficacy and safety study [abstract]. Hepatology. 2000;43(4 pt 2):444A. Abstract 1139.
33. Ideo G, Angelico M, Chirianni A, et al. Pegylated 40KDA IFN a-2a plus amantadine (AMA) or ribavirin (RBV) in naïves with chronic hepatitis C (CHC): the HIMPCT (Hepatitis Italian Multicenter Pegasys Amantadine Cooperative trial). Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 209.
34. Mangia A, Ricci G, Minerva N, et al. A 3-arm randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naïve patients with chronic HCV hepatitis. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 185.
35. Buti M, Lurie Y, Sanchez F, et al. Two doses of peg-interferon alfa 2b plus ribavirin in genotype 1 naïve patients with chronic hepatitis. Abstract presented at: 37th Annual Meeting of the European Association for the Study of Liver; April 18-21, 2002; Madrid, Spain. Abstract 655.